• Established Efficacy
  • Recapturable Results

Efficacy Established in a Worldwide Trial

In adult chronic moderate to severe plaque psoriasis, ENBREL has demonstrated rapid and sustained efficacy*, including sustained improvement in symptoms from 12–24 weeks in a worldwide plaque psoriasis clinical trial.4-7
Learn more

 *Median time for achieving a PASI 75 response was approximately 2 months.

ENBREL Recaptured Almost All of Initial Response

The data in these graphs are not meant to establish a
dosing protocol for retreatment.
ENBREL recaptured almost all of initial response in patients at 12 weeks after retreatment at both 50 mg BIW and 25 mg BIW.4,7,8

85% of surveyed physicians (n = 304) agree that moderate to severe plaque psoriasis patients on biologic therapy take planned or unplanned "drug holidays" at some point during treatment.4*

Learn more

 *In an online Harris Poll survey, 304 dermatologists were asked, "Please indicate whether you disagree, agree, or neither agree nor disagree with the following statement: Moderate to severe plaque psoriasis patients on biologic therapy sometimes take planned or unplanned 'drug holidays' at some point during treatment."


 
INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw 75% skin clearance in their moderate to severe plaque psoriasis in 3 months with ENBREL. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months. ENBREL can work fast; many patients saw improvement within 2 months. Your results may vary.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Over 1.5 million Americans are affected by moderate to severe plaque psoriasis.1,2

1. National Psoriasis Foundation. About Psoriasis/Statistics. http://www.psoriasis.org/learn_statistics. Accessed 1/11/13.

2. National Psoriasis Foundation. About Psoriasis/Types/Plaque. http://www.psoriasis.org/about-psoriasis/types. Accessed 1/11/13.

3. Jacobson CC et al. Psoriasis. In: Psoriasis and Psoriatic Arthritis: An Integrated Approach. 2005:47-56.

The Science of ENBREL

ENBREL blocks the activity of excess active tumor necrosis factor (TNF) to reduce the inflammation that causes plaques.

Discover the attributes
of ENBREL arrow

Steve's plaque psoriasis used to be a huge interference in his life.

Today, Steve uses ENBREL and is relieved that his symptoms have improved.

"It's such a relief to get on with my life."
Home
Close